Acrux Limited (ACR)
ASX ASX Primary 
XFRA Summary
Acrux Limited (ACR) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Acrux Limited ever had a stock split?
Acrux Limited Profile
| Biotechnology Industry | Healthcare Sector | Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus CEO | ASX Exchange | AU000000ACR3 ISIN |
| AU Country | - Employees | 18 Aug 2015 Last Dividend | - Last Split | - IPO Date |
Overview
Acrux Limited, operating together with its subsidiaries, focuses on the development and commercialization of a wide range of pharmaceutical products both in the generic and topical domains. The company has established its presence not only in its home country, Australia but has broadened its market reach across Europe, the United States, and in other international territories. Since its inception in 1998, Acrux Limited has grown to become a reputable name in the pharmaceutical industry, keeping its base in West Melbourne, Australia. The company is known for employing innovative methods to deliver effective treatment solutions across various therapeutic areas.
Products and Services
- Testosterone Solutions:
A critical segment of Acrux's product line includes testosterone solutions, aimed primarily at treating male patients. This range features a variety of administration methods to cater to diverse patient needs and preferences, including oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels. These products target males requiring testosterone replacement or supplementation therapy.
- Estradiol Transdermal Sprays:
For women experiencing menopause, Acrux offers estradiol transdermal sprays under the brand names Evamist and Lenzetto. These sprays are designed to provide relief from common menopausal symptoms such as hot flushes, thereby improving the quality of life for women undergoing this transitional phase.
- Lidocaine and Prilocaine Cream:
In the domain of local anesthetics, Acrux has developed a generic version of EMLA cream, which contains a combination of lidocaine and prilocaine. This topical anaesthetic is indicated for use on normal intact skin for local analgesia, genital mucous membranes for superficial minor surgery, and as a pre-treatment for infiltration anaesthesia. The versatility and effectiveness of this cream make it a valuable addition to any medical practice that performs minor surgical procedures or requires topical anaesthesia.
